Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Core Insights - Rigel Pharmaceuticals reported strong financial results for Q4 and full year 2025, with record net product sales and total revenues, setting a positive outlook for 2026 [1][2] Financial Performance - Total revenues for Q4 2025 were approximately $69.8 million, including net product sales of $65.4 million, a 41% increase from Q4 2024 [2][4] - For the full year 2025, total revenues reached approximately $294.3 million, with net product sales of $232.0 million, reflecting a 60% increase from 2024 [2][4] - Rigel reported a net income of $268.1 million for Q4 2025 and $367.0 million for the full year, significantly up from $14.3 million in Q4 2024 [2][4] Product Sales - Net product sales for TAVALISSE® were $45.6 million in Q4 2025, a 47% increase from Q4 2024, while GAVRETO® and REZLIDHIA® saw sales of $10.2 million and $9.6 million respectively, marking increases of 27% and 29% [2][4] - For the full year 2025, TAVALISSE® sales were $158.8 million, GAVRETO® sales were $42.1 million (up 146%), and REZLIDHIA® sales were $31.0 million (up 35%) compared to 2024 [2][4] Clinical Development - Enrollment in the Phase 1b study of R289 for lower-risk MDS is ongoing, with completion expected in the second half of 2026 [1][2] - The FDA approved a supplemental New Drug Application for GAVRETO, adding a boxed warning regarding serious infections [1][2] - Rigel presented data at the ASCO-GI symposium showing a 67% overall response rate for pralsetinib in patients with RET fusion-positive solid tumors [1][2] 2026 Outlook - Rigel anticipates total revenues of approximately $275 to $290 million for 2026, including net product sales of $255 to $265 million and positive net income [1][2]